Bevacizumab in Inflammatory Eye Disease

American Journal of Ophthalmology

Volumn 148, Issue 5, 2009, Pages

  Lott, McGregor N ^a   Schiffman, Joyce C ^a   Davis, Janet L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BEVACIZUMAB; CORTICOSTEROID; MOXIFLOXACIN; TRIAMCINOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE STUDY; CHILD; CLINICAL ARTICLE; DRUG EFFECT; ENDOPHTHALMITIS; EYE EXAMINATION; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; INTERVENTION STUDY; INTRAOCULAR HYPOTENSION; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; SCHOOL CHILD; SUBRETINAL NEOVASCULARIZATION; THICKNESS; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY;

EID: 70350575763     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.06.010     Document Type: Article

References (33)

1. Watzke R.C., Packer A.J., Folk J.C., Benson W.E., Burgess D., and Ober R.R. Punctate inner choroidopathy. Am J Ophthalmol 98 (1984) 572-584
2. Olk R.J., Burgess D.B., and McCormick P.A. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis. Ophthalmology 91 (1984) 1592-1602
3. Chew E.Y., and Crawford J. Sympathetic ophthalmia and choroidal neovascularization. Case report. Arch Ophthalmol 106 (1988) 1507-1508
4. Rothova A., Suttorp-van Schulten M.S., Frits T.W., and Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80 (1996) 332-336
5. Brown Jr. J., Folk J.C., Reddy C.V., and Kimura A.E. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 103 (1996) 1100-1105
6. Rothova A., Berendschot T.T., Probst K., van Kooij B., and Baarsma G.S. Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology 111 (2004) 954-959
7. Rosenberg K.D., Feuer W.J., and Davis J.L. Ocular complications of pediatric uveitis. Ophthalmology 111 (2004) 2299-2306
8. Markomichelakis N.N., Halkiadakis I., Pantelia E., et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111 (2004) 946-953
9. Lim W.K., Buggage R.R., and Nussenblatt R.B. Serpiginous choroiditis. Surv Ophthalmol 50 (2005) 231-244
10. Aiello L.P. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29 (1997) 354-362
11. Fine H.F., Baffi J., Reed G.F., Csaky K.G., and Nussenblatt R.B. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132 (2001) 794-796
12. Van Wijngaarden P., Coster D.J., and Williams K.A. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293 (2005) 1509-1513
13. Martidis A., Miller D.G., Ciulla T.A., Danis R.P., and Moorthy R.S. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 15 (1999) 425-428
14. Rogers A.H., Duker J.S., Nichols N., and Baker B.J. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 110 (2003) 1315-1320
15. Wachtlin J., Heimann H., Behme T., and Foerster M.H. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 241 (2003) 899-906
16. Leslie T., Lois N., Christopoulou D., Olson J.A., and Forrester J.V. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 89 (2005) 147-150
17. Nowilaty S.R., and Bouhaimed M. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 90 (2006) 982-986
18. Lim J.I., Flaxel C.J., and LaBree L. Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease. Ann Acad Med Singapore 35 (2006) 198-202
19. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10 (2002) 239-246
20. Papadaki T., Zacharopoulos I., Iaccheri B., Fiore T., and Foster C.S. Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 13 (2005) 469-470
21. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
22. Bashshur Z.F., Bazarbachi A., Schakal A., Haddad Z.A., El Haibi C.P., and Noureddin B.N. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
23. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143 (2007) 977-983
24. Fine H.F., Baffi J., Reed G.F., Csaky K.G., and Nussenblatt R.B. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132 (2001) 794-796
25. Seth R.K., Stoessel K.M., and Adelman R.A. Choroidal neovascularization associated with West Nile virus chorioretinitis. Semin Ophthalmol 22 (2007) 81-84
26. Margolis R., Lowder C.Y., Sears J.E., and Kaiser P.K. Intravitreal bevacizumab for macular edema due to occlusive vasculitis. Semin Ophthalmol 22 (2007) 105-108
27. Adan A., Navarro M., Casaroli-Marano R.P., Ortiz S., and Molina J.J. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 245 (2007) 1873-1875
28. Kurup S., Lew J., Byrnes G., Yeh S., Nussenblatt R., and Levy-Clarke G. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol 87 (2009) 349-352
29. Adan A., Mateo C., Navarro R., Bitrian E., and Casaroli-Marano R.P. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27 (2007) 1180-1186
30. Chang L.K., Spaide R.F., Brue C., Freund K.B., Klancnik Jr. J.M., and Slakter J.S. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 126 (2008) 941-945
31. Cordero Coma M., Sobrin L., Onal S., Christen W., and Foster C.S. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114 (2007) 1574-1579
32. Ziemssen F., Deuter C.M., Stuebiger N., and Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol 245 (2007) 917-918
33. Mackensen F., Heinz C., Becker M.D., and Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28 (2008) 41-45